Ma Chun-Hui, Hu Hai-Xu, Zhang Li-Juan, Liu Yi, Liu Tian-Yi
1. School of Basic Medical Sciences, Anhui Medical University, Hefei 230032, China.
2. The Fifth Medical Center of People's Liberation Army General Hospital, Beijing 100071, China.
Yi Chuan. 2023 Mar 20;45(3):250-260. doi: 10.16288/j.yczz.22-358.
The objective of this study was to establish and verify a digital PCR assay for the detection of gene expression, and to use it to detect circulating tumor cells (CTC) by taking advantages of its ultra-high sensitivity and absolute quantitation. Firstly, the primers and probes were designed according to the mRNA sequence of gene, and housekeeping gene was used as the internal control. The best candidate was screened by human breast cancer MCF7 cells and healthy human leukocytes from 13 sets of primer and probes and verified by direct sequencing. Secondly, after the reaction conditions of the selected primers and probes were optimized, limit of blank (LOB) analysis were performed with different concentrations of cDNAs as templates from healthy human leukocytes. The results revealed the LOB of with copy numbers of 20,000, 15,000, 10,000, 5000 and 2500 were 9.24, 8.93, 3.12, 3.17 and 2.53 copies, respectively. Thirdly, the different concentrations of cDNAs from MCF7 cells and healthy human leukocytes were premixed and used in the limit of detection (LOD) analysis, which showed that the gene could be effectively detected at the concentration ratio of 50%, 10%, 5%, 1%, 0.5% and 0.1%, and the linear value was 0.9998. Finally, the preliminary results of digital PCR in clinical samples indicated that copy numbers were higher in advanced breast cancer patients than healthy controls. The above results demonstrated the advantages of our digital PCR assay in sensitivity, specificity, and accurate quantification. If verified further, the assay is expected to play significant roles in the quantitative analysis of CTC in breast cancer with a good application prospect.
本研究的目的是建立并验证一种用于检测基因表达的数字PCR检测方法,并利用其超高灵敏度和绝对定量的优势来检测循环肿瘤细胞(CTC)。首先,根据基因的mRNA序列设计引物和探针,并以内参基因作为内部对照。通过人乳腺癌MCF7细胞和13组引物及探针组合中的健康人白细胞筛选出最佳候选引物和探针,并通过直接测序进行验证。其次,在优化所选引物和探针的反应条件后,以来自健康人白细胞的不同浓度cDNA为模板进行空白限(LOB)分析。结果显示,当模板cDNA拷贝数为20,000、15,000、10,000、5000和2500时,LOB分别为9.24、8.93、3.12、3.17和2.53拷贝。第三,将来自MCF7细胞和健康人白细胞的不同浓度cDNA进行预混合,并用于检测限(LOD)分析,结果表明在浓度比为50%、10%、5%、1%、0.5%和0.1%时能够有效检测该基因,线性R值为0.9998。最后,临床样本的数字PCR初步结果表明,晚期乳腺癌患者的拷贝数高于健康对照。上述结果证明了我们的数字PCR检测方法在灵敏度、特异性和准确定量方面的优势。如果进一步验证,该检测方法有望在乳腺癌CTC的定量分析中发挥重要作用,具有良好的应用前景。